Novartis (Swiss: NOVN) received FDA approval for Rhapsido (remibrutinib), an oral treatment for adult patients with chronic spontaneous urticaria who ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE